Effects of Timing of Everolimus Transition on Renal Outcomes in Liver Transplant Recipients
Mary Leick, Hannah Belleau, Timothy McCashland, Richa Sharma · 2026
Read Effects of Timing of Everolimus Transition on Renal Outcomes in Liver Transplant Recipients by Mary Leick, Hannah Belleau, Timothy McCashland, Richa Sharma (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13621813.txt.
Description
Mary Leick and three co-authors review records of liver transplant patients who switched to everolimus, a drug used to lower reliance on older immune-suppressing medicines that can harm the kidneys. The question was whether the timing of the switch changes kidney outcomes. Patients at one academic medical centre were grouped by how soon after transplant the switch happened.
Eighty patients were included. Those switched within six months showed kidney gains that held at one month and at twelve months after the change. A later group gained at one month but not at twelve, and the latest group gained at neither point. The trade-off was rejection, proven by tissue sampling, which was most common in the earliest group. The authors conclude that early switching protects kidneys best but needs care because rejection risk runs high.
Catalog record
| CREATOR | Mary Leick, Hannah Belleau, Timothy McCashland, Richa Sharma |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |